New press release out: HCS Pharma, LumiSTAR Biotech & MolDev explore stem cell-derived organoids for drug screening

In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…

Collaboration between “Institut du thorax” and HCS Pharma: improving the management of hypercholesterolemia using a relevant and innovative organoid-based in vitro liver model

Launched in 2016, the adventure is coming to an end after 5 years of work carried out within the RHU CHOPIN (CHOlesterol Personalized INnovation), and with a strong collaboration between HCS Pharma and l’Institut du thorax. This collaborative project of national scope was led by Professor Bertrand Cariou, director of Read more…

Poster – Urine sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia

Human induced pluripotent stem cells (hiPSC) are becoming a relevant model for the study of liver metabolic diseases once differentiated into hepatocyte-like cells (HLC), and it has been shown that they can faithfully recapitulate autosomal dominant hypercholesterolemia (ADH). PCSK9 is a critical modulator of cholesterol homeostasis, and quickly became a Read more…